Intravenous thrombolysis for ischaemic stroke: short delays and high community-based treatment rates after organisational changes in a previously inexperienced centre
- 1Department of Neurology, Sørlandet Hospital Kristiansand, Norway
- 2Department of Neurology, Haukeland University Hospital, Bergen, Norway
- 3Institute of Clinical Medicine, University of Bergen, Bergen, Norway
- 4Hospital of Rehabilitation, Rikshospitalet University Hospital, Kristiansand, Norway
- Dr A Tveiten, Department of Neurology, Sorlandet Sykehus Kristiansand, 4604 Kristiansand, Norway;
- Accepted 30 September 2008
Aim: To evaluate hospital delays in thrombolytic treatment before and after organisational changes and community-based treatment rates in a previously inexperienced centre.
Methods: The delays before and after organisational changes made in 2006 were compared using a prospective treatment database. In a 6-month period in 2007, a community-based search was performed for all hospitalisations for ischaemic stroke. The number of patients admitted within the 0–3 h time window and the proportion treated with tissue plasminogen activator were analysed.
Results: The number of treatments increased fourfold from 2005 to 2007 with a significant reduction in mean door-to-needle time from 60 min to 38 min (p = 0.002). In the community-based series, 14/137 patients (10%) hospitalised with ischaemic stroke and 13/32 patients (41%) admitted in the 0–3 h window were treated.
Conclusions: An inexperienced stroke centre can rapidly implement the necessary logistics to deliver thrombolysis to a large proportion of patients with acute stroke with short hospital delays. Important factors are probably prenotification of a team and the initiation of thrombolytic treatment in the emergency room.
Competing interests: AT and LT have received travel grants and honoraria from Boehringer Ingelheim GmbH.